

This is the peer reviewed version of the following article:

Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β -globin locus / Antoniani, C.; Meneghini, V.; Lattanzi, A.; Felix, T.; Romano, O.; Magrin, E.; Weber, L.; Pavani, G.; Hoss, S. E.; Kurita, R.; Nakamura, Y.; Cradick, T. J.; Lundberg, A. S.; Porteus, M.; Amendola, M.; Nemer, W. E.; Cavazzana, M.; Mavilio, F.; Miccio, A.. - In: BLOOD. - ISSN 0006-4971. - 131:17(2018), pp. 1960-1973. [10.1182/blood-2017-10-811505]

Terms of use:

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

26/04/2024 07:52

(Article begins on next page)

Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β -globin locus

Running head: HbF reactivation for treating hemoglobinopathies.

Chiara Antoniani^{1,2}, Vasco Meneghini^{1,2}, Annalisa Lattanzi³, Tristan Felix^{1,2}, Oriana Romano^{1,2,4}, Elisa Magrin^{5,10}, Leslie Weber^{2,5}, Giulia Pavani³, Sara El Hoss⁶, Ryo Kurita⁷, Yukio Nakamura⁷, Thomas J Cradick⁸, Ante S Lundberg⁸, Matthew Porteus⁹, Mario Amendola³, Wassim El Nemer⁶, Marina Cavazzana^{2,5,10,11}, Fulvio Mavilio^{3,4}, and Annarita Miccio^{1,2,3}.

¹Laboratory of chromatin and gene regulation during development, Imagine Institute, INSERM UMR1163, Paris, France

²Paris Descartes, Sorbonne Paris Cité University, Imagine Institute, Paris, France

³Genethon, INSERM UMR951, Evry, France

⁴Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy

⁵Laboratory of Human Lymphohematopoiesis, INSERM UMR1163, Paris, France

⁶Sorbonne Paris Cité University, Paris Diderot University, INSERM, Institut National de la Transfusion Sanguine (INTS) Unité Biologie Intégrée du Globule Rouge, Laboratoire d'Excellence GR-Ex, Paris, France

⁷RIKEN Tsukuba Branch, Ibaraki, Japan

⁸CRISPR Therapeutics, Cambridge, MA, USA

⁹Department of Pediatrics, Stanford University, Stanford, CA, US

¹⁰Biotherapy Department, Necker Children's Hospital, AP-HP, Paris, France

¹¹Biotherapy Clinical Investigation Center, Groupe Hospitalier Universitaire Ouest, AP-HP, Paris, France

C.A. and V.M contributed equally to this study.

Corresponding Author: Annarita Miccio, Imagine Institute, 24, Boulevard du Montparnasse, 75015 Paris, France. E-mail address: annarita.miccio@institutimagine.org.

Tel: +33142754334

Statement of prior presentation: Presented in abstract form at the 58th annual meeting of the American Society of Hematology, San Diego, CA, December 4, 2016.

Word count (abstract): 147

Word count (text): 4282

Figure count: 6

Table count: 0

Reference count: 70

Scientific category: Red cells, Iron and Erythropoiesis; Gene therapy.

KEY POINTS

1. CRISPR/Cas9-mediated disruption of the β -globin locus architecture re-activates fetal γ -globin expression in adult erythroblasts.
2. Fetal γ -globin re-activation and sickle β -globin down-regulation leads to the amelioration of the sickle cell disease cell phenotype.

ABSTRACT

Naturally occurring, large deletions in the β -globin locus result in hereditary persistence of fetal hemoglobin, a condition that mitigates the clinical severity of sickle-cell disease (SCD) and β -thalassemia. We designed a CRISPR/Cas9 strategy to disrupt a 13.6-kb genomic region encompassing the δ - and β -globin genes and a putative γ - δ intergenic fetal hemoglobin (HbF) silencer. Disruption of just the putative HbF silencer results in a mild increase in γ -globin expression, whereas deletion or inversion of a 13.6-kb region causes a robust re-activation of HbF synthesis in adult erythroblasts, associated with epigenetic modifications and changes in the chromatin contacts within the β -globin locus. In primary, SCD patient-derived hematopoietic stem/progenitor cells, targeting the 13.6-kb region results in high proportion of γ -globin expression in erythroblasts, increased HbF synthesis, and amelioration of the sickling cell phenotype. Overall, this study provides clues for a potential genome editing approach to the therapy of β -hemoglobinopathies.

INTRODUCTION

β -thalassemia and sickle cell disease (SCD) are severe anemias caused by mutations in the β -globin gene cluster. In β -thalassemia, the reduced production of adult β -chains causes α -globin precipitation, ineffective erythropoiesis and insufficiently hemoglobinized red blood cells (RBC). In SCD, the $\beta\text{Glu}\rightarrow\text{Val}$ substitution leads to Hb polymerization and RBC sickling, which is responsible for vaso-occlusive crises, hemolytic anemia and organ damage. Current treatment of SCD and β -thalassemia involves regular RBC transfusion, which is associated with significant side effects, such as iron overload and organ damage. The only definitive cure for β -hemoglobinopathies is allogeneic hematopoietic stem cell (HSC) transplantation from HLA-matched sibling donors, which is available only to a fraction of the patients¹⁻⁴. Transplantation of autologous, genetically corrected HSC is an attractive therapeutic alternative for patients lacking a compatible intrafamilial donor^{5,6}.

The clinical course of β -hemoglobinopathies is ameliorated by elevated levels of fetal γ -globin, which reduces globin chain imbalance in β -thalassemias and exerts a potent anti-sickling effect in SCD. Naturally occurring large deletions encompassing the β - and δ -globin genes result in a congenital increase of HbF expression known as hereditary persistence of fetal hemoglobin (HPFH), which ameliorates both thalassemic and SCD phenotypes. Large HPFH deletions are thought to eliminate HbF inhibitory sequences or juxtapose the γ -globin promoters to remote enhancer regions⁷. Several studies demonstrated that BCL11A, a transcriptional repressor, is required to maintain silencing of HbF expression^{8,9}. BCL11A interacts with GATA1, FOG1, SOX6 and the NuRD repressor complex and occupies critical sites within the β -globin gene cluster, including sequences specifically deleted in HPFH individuals^{10,11}. These observations provide a strong rationale for developing gene therapy

and genome editing¹²⁻¹⁹ approaches to the treatment of β -hemoglobinopathies aimed at inducing a β -to- γ globin reverse switching.

Here, we integrated transcription factor binding site analysis and HPFH genetic data to define *cis*-regulatory elements in the β -globin locus involved in γ -globin gene silencing. We designed CRISPR/Cas9 nucleases disrupting: (i) a potential γ - δ intergenic HbF silencer containing a putative BCL11A binding site¹⁰; (ii) the shortest deletion associated with elevated HbF levels in β -thalassemic patients (“Corfu” deletion), encompassing the putative γ - δ intergenic HbF silencer²⁰⁻²²; (iii) an extended, 13.6-kb genomic region including the δ - and β -globin genes and the putative intergenic HbF silencer. Disrupting the 13.6-kb region led to a robust HbF re-activation and a concomitant reduction in β -globin expression in an adult erythroid cell line²³ and in healthy donor and SCD hematopoietic stem/progenitor cells (HSPC)-derived erythroblasts.

METHODS

Cell culture

HUDEP-2 cells were cultured and differentiated, as described in Canver et al.¹⁴. Genome-edited HUDEP-2 bulk populations were cloned by limiting dilution and clones harboring deletion or inversion were screened by PCR and ddPCR. Healthy donor HSPC were differentiated towards the erythroid lineage as previously described⁸. SCD HSPC were terminally differentiated in RBC using a 3-phase erythroid culture system²⁴.

Cell transfection

Cells were transfected with 4 ug of a Cas9-GFP expressing plasmid and 0.8-1.6 ug of each gRNA-containing vector using Nucleofector I (Lonza). We used AMAXA Cell Line Nucleofector Kit V (VCA-1003) for K562 and HUDEP-2 (T16 and L-29 programs) and AMAXA Human CD34 Cell Nucleofector Kit (VPA-1003) for HSPC (U-08 program). GFP⁺ cells were sorted using SH800 Cell Sorter (Sony Biotechnology).

Chromosome conformation capture (3C) and ChIP assays

3C and ChIP assays were performed on differentiated HUDEP-2 clones, as previously described^{25,26}.

Sickling assay

In vitro generated SCD RBC were exposed to an oxygen-deprived atmosphere (0% O₂) and the time-course of sickling was monitored in real-time by video microscopy for 1 hour, capturing images every 5 minutes using the AxioObserver Z1 microscope (Zeiss) and a 40X objective. Images of the same fields were taken throughout all stages and processed with ImageJ to determine the percentage of sickled RBC per field of acquisition in the total RBC population.

RESULTS

Identification of potential therapeutic targets for HbF re-activation in the β -globin locus

In HPFH individuals, genomic deletions encompassing the β - and δ -globin genes lead to therapeutic HbF levels. In contrast, in deletional β - and $\delta\beta$ -thalassemias HbF synthesis is not sufficient to allow a functional RBC maturation. An exhaustive comparison of large (>7 kb) genomic deletions associated with either HPFH or β^0 - and $\delta\beta^0$ -thalassemias identified a 3.5-kb γ - δ intergenic region absent in 10 out of 12 HPFH deletions that represents a potential cis-regulatory element involved in HbF silencing (**Figure 1** and **Figure S1**). By reanalyzing publicly available ChIP-Seq data²⁷, we identified in this region binding sites for the erythroid-specific master transcription factor GATA1 in adult but not in fetal primary erythroblasts (**Figure 1**). The 3.5-kb region contains SNPs associated with high HbF levels^{28,29}, binding sites for the chromatin remodeling PVR complex, which may be involved in HbF silencing³⁰, and a putative BCL11A binding site^{10,31} (**Figure 1**). The same region is devoid of histone modifications associated with either active (H3K27ac and H3K36me3) or repressive (H3K27me3 and H3K9me3) chromatin states²⁷ in both fetal and adult erythroblasts (**Figure 1**), while it is enriched in H3K36 dimethylation (H3K36me2), a histone modification that may generate a repressive chromatin environment^{27,32,33}. H3K36me2 is in fact enriched in fetal globin genes in adult erythroblasts and in adult globin genes in fetal erythroblasts (**Figure 1**). The 3.5-kb γ - δ intergenic region is included in the 7.2-kb Corfu deletion, the minimal deletion resulting in HbF elevation in β -thalassemic patients³⁴ (**Figure 1**). In contrast, 13 out of 19 deletions causing β^0 - and $\delta\beta^0$ -thalassemias do not include the 3.5-kb region and/or the putative BCL11A binding site (**Figure 1** and **Figure S1**). Of the six $\delta\beta^0$ -thalassemia deletions removing the 3.5-kb region, two (Thai³⁵ and

Black³⁶ $\delta\beta^0$ -thalassemias) are associated with extremely high (25%) HbF levels that significantly improve β -thalassemic and SCD phenotypes, while the remaining ones are associated with a mild thallemic phenotype in heterozygous and homozygous patients^{10,37-40} (**Figure S1**).

This analysis suggests that the 3.5-kb γ - δ intergenic region and the 7.2-kb Corfu region represent potential therapeutic targets to achieve HbF re-activation by a targeted deletion approach (**Figure 1**). In addition, we designed a larger, 13.6-kb deletion starting from the 5' breakpoint of the Corfu deletion and extending further 3' to include the promoter and first exon of the β -globin gene, similar to the naturally occurring 12.9-kb HPFH-5 deletion⁴¹ (**Figure 1** and **Figure S1**). Compared to the HPFH-5, the 13.6-kb deletion leaves intact the 3' and intronic enhancers of the β -globin gene that, upon juxtaposition to the γ -globin genes, may further enhance their expression (**Figure 1** and **Figure S1**). In SCD patients, the 13.6-kb deletion would simultaneously up-regulate γ -globin synthesis and inactivate the β^S -globin gene.

Disruption of the 13.6-kb region re-activates fetal γ -globin expression in an adult erythroblastic cell line

To generate the deletion of the target regions, we designed 18-bp single guide RNAs (gRNAs)⁴² recognizing the 5' and 3' ends of the selected genomic loci (**Figure S2A**). For each target site, 3 to 5 gRNAs (**Table S1**) were individually delivered, together with a Cas9-GFP fusion protein, in K562 erythroid cells by plasmid transfection. We selected efficient gRNAs able to generate InDels in the target sites with an efficiency of $\geq 55\%$ in the Cas9-GFP⁺ cells (**Figure S2B and C**). Pairs of the selected gRNAs successfully generated 3.5, 7.2 and 13.6-kb deletions in up to 31% of the alleles, and inversions of the same regions at lower frequencies (**Figure S2D**). At the remaining loci, we measured up to 68% of small InDels at

both 5' and 3' gRNA target sites without excision or inversion of the intervening sequence (**Figure S2D**).

To evaluate HbF re-activation upon CRISPR/Cas9-mediated disruption of the targeted regions, we transfected plasmids encoding Cas9-GFP and gRNA pairs into HUDEP-2 erythroid cells, expressing mainly adult β -globin²³. The deletion and inversion frequency was $25\pm 8\%$ and $39\pm 3\%$, respectively for the 13.6-kb region, $27\pm 6\%$ and $21\pm 11\%$ for the 7.2-kb region, $18\pm 3\%$ and $6\pm 2\%$ for the 3.5-kb region. Minimal InDel frequency was observed at the top-predicted off-target sites (**Table S2**). The frequency of deletion/inversion events did not change upon terminal differentiation, thus excluding negative selection of genome-edited cells during erythroid maturation (**Figure S3A**). Morphological analysis of cell cultures revealed no differences between genome-edited and control cells (**Figure 2A**), indicating that erythroid differentiation is not affected by disruption of the β -globin locus. The expression of transcription factors involved in hemoglobin switching and HbF silencing did not change in control and treated samples (**Figure S3B**). Terminally differentiated HUDEP-2 bulk populations harboring deletion and inversion of the 13.6-kb showed a dramatic increase in γ -globin mRNA levels and concomitant decrease in β - and δ -globin expression (**Figure 2B**). FACS analysis showed a substantial increase in the proportion of F-cells compared to control samples (**Figure 2C**). Reverse-phase (RP)-HPLC analysis confirmed re-activation of A γ and G γ -globin chains and decrease in β -globin expression (**Figure 2D and E**). Interestingly, the extent of genome editing in the 13.6-kb region was positively correlated with the increase in the percentage of F-cells and HbF production (**Figure S4**).

In contrast, deletion and inversion of the Corfu region or of the 3.5-kb putative HbF silencer did not significantly increase γ -globin expression (**Figure 2B, C and D**) in differentiated bulk populations of HUDEP-2 cells. These results were confirmed in HUDEP-2 clones harboring bi-allelic deletions, which showed no increase in primary and mature γ -

globin gene transcripts and HbF accumulation (**Figure S5A, B and C**).

To correlate HbF re-activation with the specific genomic modifications of the 13.6-kb region, we generated clones harboring bi-allelic or mono-allelic 13.6-kb deletions (del/del, del/wt) or inversions (inv/inv and inv/wt). Sequencing of the targeted region showed in the vast majority of the cases the expected repaired junctions in both deleted and inverted alleles, with small InDels (**Figure 3A**). Erythroid differentiation was not impaired in genome-edited clones compared to control cells (**Figure S6A**). We observed increased γ -globin expression levels and HbF production in clones harboring bi-allelic deletions or inversions, whereas mono-allelic deletion/inversion of the 13.6-kb region determined a mild re-activation of HbF (**Figure 3B and C**). As expected, β -globin expression was not detected in bi-allelic clones and decreased in mono-allelic clones (**Figure 3B**). δ -globin mRNA was absent in clones harboring bi-allelic deletions and significantly reduced in inv/inv, del/wt and inv/wt clones (**Figure 3B**).

Chromatin conformation capture (3C) experiments showed an increased interaction frequency between the LCR and the γ -globin promoters in clones harboring bi-allelic deletions or inversions (**Figure 3D**). We observed increased levels of H3K27 acetylation, a marker of active regulatory elements, at the γ -globin promoters in both del/del and inv/inv clones (**Figure 3E**). 3C experiments indicated a reduced interaction between the LCR and the genomic region containing the adult β - and δ -globin genes in clones harboring the inversion of the 13.6-kb region (**Figure S6B**). Interestingly, deletion of the 13.6-kb region led to a high interaction frequency between the γ -globin promoter and a genomic region containing the 3' and intronic enhancers of the β -globin gene, the HBBP1 pseudogene and the β -globin locus transcript 3 (BGLT3) gene (**Figure S6C**).

Induction of γ -globin expression in primary erythroblasts differentiated from genome-edited HSPC

Cas9-GFP and gRNAs targeting the 13.6-, 7.2- and 3.5-kb regions were delivered by plasmid transfection to G-CSF-mobilized HSPC from healthy donors, and GFP⁺ sorted cells were differentiated in liquid culture towards the erythroid lineage (**Figure 4A**). In mature erythroblasts, the deletion and inversion frequency was 18±3 and 17±2%, respectively for the 13.6-kb region, 19±7 and 19±6% for the 7.2-kb region, 17±2 and 7±1% for the 3.5-kb region (**Figure 4B**). qRT-PCR showed a ~4-fold increase in γ -globin expression and a parallel reduction in β -globin mRNA levels in 13.6-kb genome-edited cells compared to control samples (**Figure 4C**). A mild (~2-fold) increase in γ -globin transcript levels was observed in 3.5- and 7.2-kb genome-edited cells (**Figure 4C**). δ -globin mRNA levels tended to decrease in all genome-edited samples (**Figure 4C**). FACS analysis revealed that the percentage of F-cells and their HbF content were increased in all genome-edited samples, with a remarkable and more prominent increment in HbF production in 13.6-kb genome-edited samples (**Figure 4D**).

We evaluated precisely the efficiency and efficacy of CRISPR/Cas9-mediated HbF induction upon targeting of the 13.6-kb region in HSPC derived from healthy donors and SCD patients. We achieved Cas9-GFP expression in 30-60% of HSPC with deletion and inversion efficiency of 7.4±0.3 and 6.8±0.5%, respectively, in unsorted treated cells. In mature erythroblasts derived from FACS-sorted Cas9-GFP⁺ genome-edited HSPC, we detected ~20% of deleted or inverted alleles (**Figure 5A**). Genome-editing efficiency was similar between pools of erythroid progenitors (BFU-E) and mature erythroblasts generated in liquid culture, in both unsorted and sorted genome-edited populations (**Figure S7A and Figure 5A**), thus indicating efficient CRISPR-Cas9-mediated genome editing in early hematopoietic progenitors. To estimate precisely the frequency of mono-/bi-allelic deletion and inversion events, we measured the editing efficiency in single BFU-E. PCR analysis of the targeted region showed a high frequency (~70%) of clones harboring mono- and bi-allelic

deletions and inversions (**Figure 5B**). We observed in the majority of the alleles the expected deletion and inversion junctions, with small Indels (**Figure 5C**). qRT-PCR analysis showed an increase in γ -globin expression and a parallel reduction in β - and δ -globin mRNA levels in genome-edited cells derived from both healthy donor and SCD HSPC, as compared to control samples (**Figure 5D**). In mature erythroblasts derived from healthy donor GFP⁺ genome-edited HSPC, the proportion of F-cells and their HbF content (MFI) were markedly increased (**Figure 5E**). RP-HPLC analysis revealed a robust increase in γ -globin protein levels (**Figure 5F and G**) representing up to 53% of the total β -like globin content (**Figure 5H**), and a 2-fold reduction of β -globin protein levels (**Figure 5F and G**). Notably, we did not observe imbalance in α - and β -like globin chain synthesis in genome-edited cells, thus indicating that the reduction of β -globin is compensated by the increased production of γ -globin chains (**Figure 5F**). On the contrary, β -globin gene knock-down, performed by using a gRNA targeting the exon 1 of the β -globin, induced a modest increase in γ -globin levels, which were insufficient to compensate the reduction of β -globin expression, thus resulting in the imbalance in α - and β -like globin chain synthesis (**Figure S8A**) and generation of α -globin aggregates, as observed in mature erythrocytes of β -thalassemic patients⁴³ (**Figure S8B**). Erythroid differentiation was not hampered upon CRISPR-Cas9-mediated genome editing, as determined by FACS analysis of erythroid markers (**Figure S8C**) and morphological analyses (**Figure S8D**). Similarly, HbF up-regulation was observed in pools of BFU-E derived from GFP⁺ genome-edited cells (**Figure S7G-I**). Mature erythroblasts derived from unsorted genome-edited HSPC showed a less pronounced but consistent increase in HbF production, as demonstrated by qRT-PCR, FACS and RP-HPLC analyses (**Figure S7B-F**). Importantly, the percentage of genome-edited alleles was directly correlated to the γ -globin mRNA and protein levels, and the increased percentage of F-cells in mature erythroblasts ($P < 0.05$; **Figure S9**).

CRISPR/Cas9-mediated HbF induction ameliorates the SCD cell phenotype

To assess the effect of HbF induction on HbS polymerization, we targeted the 13.6-kb region in bone marrow-derived (SCD donor 1) or mobilized (SCD donor 2) HSPC from SCD patients. Cells were mobilized by Plerixafor, since administration of G-CSF leads to severe adverse events in SCD patients⁴⁴. The deletion and inversion frequency was 17.2 and 15.6% for donor 1 and 34.1 and 28.1% for donor 2. Edited HSPC were terminally differentiated into enucleated RBC with no impairment in the erythroid maturation (**Figure S10A, B and C**). FACS analysis showed an increase in the percentage of F-cells and their HbF content in the genome-edited population (**Figure 6A**). RP-HPLC analysis confirmed a substantial increase of γ -globin chains and a concomitant reduction of β^S -globin levels (**Figure 6B and C**), resulting in an inversion of the β -to- γ globin ratio (**Figure 6D**). To analyze the effect of HbF up-regulation on RBC sickling, we used an *in vitro* sickling assay that measures the proportion of sickle-shaped RBC under induced hypoxia. In control SCD cells, induction of HbS polymerization at 0% O₂ led to an increase in the fraction of sickled cells up to ~65% of the total RBC (**Figure 6E and Figure S10D**). In the genome-edited RBC population, we observed a lower proportion of sickled cells reaching a maximum of ~30% of the total RBC (**Figure 6E**), thus showing that the increase of HbF expression causes an amelioration of the SCD phenotype in cultured cells.

DISCUSSION

Reactivation of HbF by genome editing may be a therapeutic approach to both β -thalassemia and SCD. To identify potential target regions, we carried out a comprehensive analysis of deletional mutations mapped in thalassemic and HPFH individuals and reanalyzed available epigenetic data on histone modifications and transcription factor binding in the β -globin locus. We identified and tested by CRISPR/Cas9-mediated disruption three target regions, i.e., a 3.5-kb γ - δ intergenic region commonly deleted in HPFH but not in $\delta\beta$ - and β -thalassemias, the 7.2-kb Corfu deletion leading to elevated HbF levels in β -thalassemic patients, and a more extended 13.6-kb deletion inactivating also the β -globin gene.

The minimal 3.5-kb region binds BCL11A and its partner GATA1 in adult erythroblasts, and represents a putative HbF silencing element¹⁰. In fetal erythroblasts, GATA1 does not bind the 3.5-kb region, suggesting that it may contribute to the recruitment of BCL11A repressor only in adult erythroblasts. Of note, the evidence that BCL11A occupies this region in primary erythroblasts is conflicting^{10,45}, leaving the possibility that HbF expression is silenced by other mechanisms. Indeed, the 3.5-kb region contains a 250-bp polypyrimidine-rich sequence targeted by the PYR repressor complex, deletion of which resulted in delayed human γ -to- β -globin switching in some transgenic mouse studies^{46,47,48}. Chromatin conformation experiments suggested that the 3.5-kb region establishes the formation of a fetal subdomain and an adult subdomain, thus enabling the LCR to activate globin expression in a stage-specific manner⁴⁹. In HPFH, removal of this region might impair the establishment of two separate sub-domains, thus allowing the LCR to interact also with the γ -globin genes in adult erythroblasts. The 3.5-kb region is contained in the 7.2-kb Corfu deletion, which leads to therapeutically high HbF levels when present in homozygosis in β -thalassemic patients. In heterozygosis, the Corfu deletion in *cis* to a β -thalassemic mutation causes a ~3-

fold elevation of γ -globin primary transcripts that is translated in elevation of γ -globin mRNA and HbF levels only when β -globin mRNA levels fall below a critical threshold³⁴.

Disruption of the 3.5-kb and the Corfu regions by CRISPR/Cas9 editing led to a modest de-repression of the fetal γ -globin genes in primary erythroblasts derived from adult HSPC. The same deletions had no effect in the HUDEP-2 adult erythroblast cell line even when carrying bi-allelic deletions, suggesting that these cells may not faithfully reproduce all aspects of adult erythropoiesis. Disruption of the putative silencer region containing a potential BCL11A binding site is therefore not sufficient *per se* to reactivate HbF synthesis at significant levels, suggesting that HbF silencing may be controlled by multiple BCL11A-bound *cis*-regulatory regions in a redundant fashion^{50,51}. However, the mild elevation of HbF synthesis in primary erythroblasts was obtained with an editing efficiency of less than 50% and in cells carrying intact β -globin genes, while in patients with increased HbF levels the Corfu deletion is always associated to a β -thalassemia trait. Further studies are therefore needed to investigate the molecular mechanisms underlying HbF re-activation upon disruption of the 3.5- and 7.2-kb regions.

Disruption of the 13.6-kb region, which extends the Corfu deletion to the first intron of the β -globin gene, caused a robust re-activation of HbF synthesis expression in primary erythroblasts as well as in HUDEP-2 cells. Genome edited erythroblasts were not counter-selected during erythroid differentiation and showed a normal α /non- α globin chain ratio, indicating that reactivation of HbF compensates for the loss of HbA synthesis and prevents precipitation of uncoupled α -globin chains and ineffective erythropoiesis, consistent with the asymptomatic HPFH phenotype.

Our results indicate that a large deletion spanning the Corfu region, the δ - β intergenic region and part of the β -globin gene is necessary to reactivate γ -globin gene expression at significant levels. Knock-down of the β -globin gene in primary HSPC-derived erythroblasts produced only a modest effect on HbF expression, and caused α /non- α chain imbalance, as

observed in β -thalassemia patients. Deletion of the β -globin promoter in β -thalassemia carriers or of the entire δ - β intergenic region in Senegalese $\delta^0\beta^+$ -thalassemia and Hb Lepore carriers likewise cause a modest increase in HbF synthesis^{52,53,54}, suggesting that β -globin gene inactivation or deletion of the δ - β intergenic region including the β -globin promoter may represent *per se* only contributing factors.

A factor contributing to HbF re-activation upon deletion of the 13.6-kb region may be the juxtaposition of the potent 3' β -globin enhancer to the γ -globin genes. Indeed, 3C experiments in HUDEP-2 clones harboring bi-allelic deletion of the 13.6-kb region showed an increased interaction of the γ -globin promoter with a region containing the 3' and intronic β -globin enhancers, suggesting a causal role of these enhancers in activating γ -globin gene expression. However, we cannot exclude an increased interaction of the γ -globin promoter also with the HBBP1 pseudogene and the BGLT3 non-coding RNA gene, both previously described to play a role in HbF regulation^{50,51} and contained in the fragment assayed in the 3C experiment.

Unexpectedly, inversion of the 13.6-kb region was as effective as its deletion in reactivating HbF synthesis, as analyzed in individual HUDEP-2 clones harboring monoallelic or biallelic inversions and in primary erythroblasts, where almost half of the edited alleles carried an inversion of the 13.6-kb region. Like the deletion, the inversion inactivates the adult β -globin gene, again suggesting that reduced β -globin expression may contribute to a robust increase in HbF synthesis. Chromatin conformation capture and histone modification analyses in HUDEP-2 clones harboring either bi-allelic deletions or inversions showed an increased interaction frequency between LCR and γ -globin promoters, with concomitant increase in H3K27 acetylation. Interestingly, in clones harboring bi-allelic inversions the interaction between the LCR and the adult β - and δ -globin gene region was reduced and associated with δ -globin down-regulation, indicating that an altered configuration of the 13.6-kb region is associated to re-engagement of the LCR to the fetal γ -gene promoters

despite the physical presence of the δ - and β -gene promoters. In addition, inversion of the putative intergenic silencer might impair its repressing activity, as observed for other silencer elements^{55,56}, and possibly prevent the formation of the fetal and adult sub-domains, enabling the LCR to interact with the γ -globin genes. Our study therefore suggests that deletions and inversions may induce chromatin conformation and/or epigenetic changes that ultimately result in γ -globin gene activation.

The effect of locus rearrangement on HbF synthesis was tested in clinically relevant adult HSPC from healthy donors or SCD patients, harvested from the BM or mobilized in peripheral blood by respectively G-CSF or Plerixafor administration. We achieved efficient deletion and inversion of the 13.6-kb region in HSPC-derived erythroblasts, with up to 70% of the BFU-E in clonogenic cultures harboring mono- or bi-allelic rearrangements. HbF represented up to ~60% of total hemoglobin in erythroid cells differentiated from genome-edited HSPC in liquid culture. Edited HSPC from SCD patients gave rise to functionally corrected mature RBC *in vitro*, as a result of the concomitant HbF induction and down-regulation of HbS synthesis. Overall, these data validate the 13.6-kb region as a potential target to induce a therapeutically-relevant β -to- γ reverse switch for the treatment of β -hemoglobinopathies.

In our study, at least half of the edited cells (~35% of the total population) carried a bi-allelic rearrangement as assayed in clonogenic culture, likely resulting in complete correction of the sickling phenotype. The clinical history of allogeneic transplantation in SCD or β -thalassemia patients suggests that a fraction of genetically corrected HSC of >20% is sufficient to achieve a therapeutic benefit given the *in vivo* selective survival of corrected RBC^{5,57-59}. Whether such a deletion/inversion frequency is achievable in repopulating stem/progenitor cells requires the development of optimized reagents and delivery technology and validation in predictive assays, such as xenotransplantation in appropriate immunodeficient mouse models (i.e., mice allowing the engraftment and erythroid

differentiation of HSC^{60,61}). Optimization of gRNAs, e.g., by the use of alternative protospacers and optimized scaffolds⁶², could be envisioned to increase the proportion of deleted and inverted alleles and minimize off-target effects. Replacement of DNA transfection with less toxic and more efficient delivery of RNA or Cas9 ribonucleoprotein complexes is an additional necessary step towards clinical translation. Of note, we reached up to 45% of deletion/inversion efficiency in unsorted primary HSPC-derived erythroblasts with Cas9 ribonucleoprotein delivery, a level that falls within the window of clinical relevance (Lattanzi et al. in preparation).

Compared to a classical gene addition approach, such as lentiviral vector-mediated expression of β -globins carrying anti-sickling mutations^{63,64}, a genome editing strategy aimed at forcing a β -to- γ -globin reverse switch would have the advantage of inducing high-level expression of the endogenous γ -globin gene at the expense of the sickle β -globin. Several groups have proposed genome editing approaches aimed at correcting the SCD mutation¹⁸, disrupting the erythroid-specific BCL11A enhancer^{14,17}, or mimicking genomic deletions or mutations in the γ -globin promoters associated with natural HPFH mutations^{13,19,65,66}, a strategy validated by clinical genetics. The generation of HPFH-like deletions/inversions described in this study relies on the non-homologous end joining (NHEJ) repair pathway. This editing strategy might be more efficient as compared to approaches based on homology directed repair (HDR)^{18,65-68} or microhomology-mediated end joining (MMEJ)¹³, given the apparent dominance of the NHEJ repair pathway in HSC^{68,69}. Disruption of the erythroid-specific BCL11A enhancer is also based on a NHEJ approach; our study, however, suggests that disruption of the β -globin locus may lead to higher HbF levels⁷⁰, although a direct comparison of different studies is difficult and hardly conclusive.

Ultimately, to be validated as therapeutically relevant options for β -hemoglobinopathies, any genome editing strategy faces a number of potential hurdles in terms of efficacy and safety. These include the development of non-toxic, large-scale editing technology based on

clinical-grade reagents, and the demonstration of precise editing of a number of long-term repopulating HSC at least comparable to the efficacious doses predicted by allogeneic transplantation data and currently achievable by classical gene addition technology. Last but not least, an additional advantage of gene editing may potentially be a reduction of the substantial cost currently associated to vector manufacturing in classical gene therapy.

ACKNOWLEDGMENTS

This work was supported by grants from AFM-Telethon (17224), European Research Council (ERC-2010-AdG, GT-SKIN; ERC-2015-AdG, GENEFORCURE), Agence nationale de la recherche (ANR-16-CE18-0004 and ANR-10-IAHU-01 “Investissements d’avenir” program) and EU Marie Curie-COFUND (PRESTIGE_2015_2_0015) and by a collaboration with CRISPR Therapeutics. We thank Jean-Antoine Ribeil for providing the SCD bone marrow samples, Fatima Amor for technical assistance and Alain Fischer and Isabelle Andre’-Schmutz for the discussion and the critical reading of the paper.

AUTHORSHIP CONTRIBUTIONS:

CA and VM designed and performed experiments, analyzed data and wrote the paper. AL, GP, TF, FA, OR, EM, LW and SEH performed experiments and analyzed data. RK and YN provided the HUDEP-2 cell line and protocols for erythroid differentiation. TJC, ASL and MP contributed to the design of the experimental strategy. MA, WEN and MC performed data analysis and interpretation. FM conceived the study and wrote the paper. AM conceived the study, designed experiments, analyzed data and wrote the paper.

CONFLICT-OF-INTEREST DISCLOSURE

TJC and ASL are employees and MP and FM are consultant of CRISPR Therapeutics. The other Authors declare no competing financial interests.

CORRESPONDENCE

Annarita Miccio, Imagine Institute, 24, Boulevard du Montparnasse, 75015 Paris, France. E-mail address: annarita.miccio@institutimagine.org.

REFERENCES

1. Besse K, Maiers M, Confer D, Albrecht M. On Modeling Human Leukocyte Antigen-Identical Sibling Match Probability for Allogeneic Hematopoietic Cell Transplantation: Estimating the Need for an Unrelated Donor Source. *Biol Blood Marrow Transplant*. 2016;22(3):410-417.
2. Saber W, Opie S, Rizzo JD, Zhang MJ, Horowitz MM, Schriber J. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. *Blood*. 2012;119(17):3908-3916.
3. Sadelain M, Boulad F, Galanello R, et al. Therapeutic options for patients with severe beta-thalassemia: the need for globin gene therapy. *Hum Gene Ther*. 2007;18(1):1-9.
4. Chandrakasan S, Malik P. Gene therapy for hemoglobinopathies: the state of the field and the future. *Hematol Oncol Clin North Am*. 2014;28(2):199-216.
5. Miccio A, Cesari R, Lotti F, et al. In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia. *Proc Natl Acad Sci U S A*. 2008;105(30):10547-10552.
6. Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. *Nature*. 2010;467(7313):318-322.
7. Forget BG. Molecular basis of hereditary persistence of fetal hemoglobin. *Ann N Y Acad Sci*. 1998;850:38-44.
8. Sankaran VG, Menne TF, Xu J, et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. *Science*. 2008;322(5909):1839-1842.
9. Guda S, Brendel C, Renella R, et al. miRNA-embedded shRNAs for Lineage-specific BCL11A Knockdown and Hemoglobin F Induction. *Molecular therapy : the journal of the American Society of Gene Therapy*. 2015;23(9):1465-1474.
10. Sankaran VG, Xu J, Byron R, et al. A functional element necessary for fetal hemoglobin silencing. *The New England journal of medicine*. 2011;365(9):807-814.

11. Ghedira ES, Lecerf L, Faubert E, et al. Estimation of the difference in HbF expression due to loss of the 5' delta-globin BCL11A binding region. *Haematologica*. 2013;98(2):305-308.
12. Deng W, Rupon JW, Krivega I, et al. Reactivation of developmentally silenced globin genes by forced chromatin looping. *Cell*. 2014;158(4):849-860.
13. Traxler EA, Yao Y, Wang YD, et al. A genome-editing strategy to treat beta-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition. *Nat Med*. 2016.
14. Canver MC, Smith EC, Sher F, et al. BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. *Nature*. 2015;527(7577):192-197.
15. Breda L, Motta I, Lourenco S, et al. Forced chromatin looping raises fetal hemoglobin in adult sickle cells to higher levels than pharmacologic inducers. *Blood*. 2016;128(8):1139-1143.
16. Brendel C, Guda S, Renella R, et al. Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype. *J Clin Invest*. 2016;126(10):3868-3878.
17. Vierstra J, Reik A, Chang KH, et al. Functional footprinting of regulatory DNA. *Nat Methods*. 2015;12(10):927-930.
18. Dever DP, Bak RO, Reinisch A, et al. CRISPR/Cas9 beta-globin gene targeting in human haematopoietic stem cells. *Nature*. 2016;539(7629):384-389.
19. Ye L, Wang J, Tan Y, et al. Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and beta-thalassemia. *Proc Natl Acad Sci U S A*. 2016;113(38):10661-10665.
20. Wainscoat JS, Thein SL, Wood WG, et al. A novel deletion in the beta-globin gene complex. *Ann N Y Acad Sci*. 1985;445:20-27.
21. Galanello R, Melis MA, Podda A, et al. Deletion delta-thalassemia: the 7.2 kb deletion of Corfu delta beta-thalassemia in a non-beta-thalassemia chromosome. *Blood*. 1990;75(8):1747-1749.

22. Traeger-Synodinos J, Tzetis M, Kanavakis E, Metaxotou-Mavromati A, Kattamis C. The Corfu delta beta thalassaemia mutation in Greece: haematological phenotype and prevalence. *Br J Haematol*. 1991;79(2):302-305.
23. Kurita R, Suda N, Sudo K, et al. Establishment of immortalized human erythroid progenitor cell lines able to produce enucleated red blood cells. *PLoS One*. 2013;8(3):e59890.
24. Giarratana MC, Kobari L, Lapillonne H, et al. Ex vivo generation of fully mature human red blood cells from hematopoietic stem cells. *Nat Biotechnol*. 2005;23(1):69-74.
25. Hagege H, Klous P, Braem C, et al. Quantitative analysis of chromosome conformation capture assays (3C-qPCR). *Nat Protoc*. 2007;2(7):1722-1733.
26. Romano O, Peano C, Tagliazucchi GM, et al. Transcriptional, epigenetic and retroviral signatures identify regulatory regions involved in hematopoietic lineage commitment. *Sci Rep*. 2016;6:24724.
27. Xu J, Shao Z, Glass K, et al. Combinatorial assembly of developmental stage-specific enhancers controls gene expression programs during human erythropoiesis. *Dev Cell*. 2012;23(4):796-811.
28. Akinsheye I, Alsultan A, Solovieff N, et al. Fetal hemoglobin in sickle cell anemia. *Blood*. 2011;118(1):19-27.
29. Lessard S, Beaudoin M, Benkirane K, Lettre G. Comparison of DNA methylation profiles in human fetal and adult red blood cell progenitors. *Genome Med*. 2015;7(1):1.
30. Bank A, O'Neill D, Lopez R, et al. Role of intergenic human gamma-delta-globin sequences in human hemoglobin switching and reactivation of fetal hemoglobin in adult erythroid cells. *Ann N Y Acad Sci*. 2005;1054:48-54.
31. Xu J, Bauer DE, Kerenyi MA, et al. Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A. *Proc Natl Acad Sci U S A*. 2013;110(16):6518-6523.
32. Ballare C, Lange M, Lapinaite A, et al. Phf19 links methylated Lys36 of histone H3 to regulation of Polycomb activity. *Nature structural & molecular biology*. 2012;19(12):1257-1265.

33. Cai L, Rothbart SB, Lu R, et al. An H3K36 methylation-engaging Tudor motif of polycomb-like proteins mediates PRC2 complex targeting. *Mol Cell*. 2013;49(3):571-582.
34. Chakalova L, Osborne CS, Dai YF, et al. The Corfu deltabeta thalassemia deletion disrupts gamma-globin gene silencing and reveals post-transcriptional regulation of HbF expression. *Blood*. 2005;105(5):2154-2160.
35. Svasti S, Paksua S, Nuchprayoon I, Winichagoon P, Fucharoen S. Characterization of a novel deletion causing (deltabeta)⁰-thalassemia in a Thai family. *Am J Hematol*. 2007;82(2):155-161.
36. Anagnou NP, Papayannopoulou T, Stamatoyannopoulos G, Nienhuis AW. Structurally diverse molecular deletions in the beta-globin gene cluster exhibit an identical phenotype on interaction with the beta S-gene. *Blood*. 1985;65(5):1245-1251.
37. Ottolenghi S, Giglioni B, Taramelli R, et al. Molecular comparison of delta beta-thalassemia and hereditary persistence of fetal hemoglobin DNAs: evidence of a regulatory area? *Proc Natl Acad Sci U S A*. 1982;79(7):2347-2351.
38. Mishima N, Landman H, Huisman TH, Gilman JG. The DNA deletion in an Indian delta beta-thalassaemia begins one kilobase from the A gamma globin gene and ends in an L1 repetitive sequence. *Br J Haematol*. 1989;73(3):375-379.
39. Shiokawa S, Yamada H, Takihara Y, et al. Molecular analysis of Japanese delta beta-thalassemia. *Blood*. 1988;72(5):1771-1776.
40. Yamashiro Y, Hattori Y, Okayama N, et al. A novel (g)gamma(a)gamma(deltabeta)⁰-thalassemia with a 27 kb deletion. *Hemoglobin*. 2005;29(3):197-208.
41. Camaschella C, Serra A, Gottardi E, et al. A new hereditary persistence of fetal hemoglobin deletion has the breakpoint within the 3' beta-globin gene enhancer. *Blood*. 1990;75(4):1000-1005.
42. Fu Y, Sander JD, Reyon D, Cascio VM, Joung JK. Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. *Nat Biotechnol*. 2014;32(3):279-284.

43. Breda L, Casu C, Gardenghi S, et al. Therapeutic hemoglobin levels after gene transfer in beta-thalassemia mice and in hematopoietic cells of beta-thalassemia and sickle cells disease patients. *PLoS One*. 2012;7(3):e32345.
44. Fitzhugh CD, Hsieh MM, Bolan CD, Saenz C, Tisdale JF. Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium? *Cytotherapy*. 2009;11(4):464-471.
45. Jawaid K, Wahlberg K, Thein SL, Best S. Binding patterns of BCL11A in the globin and GATA1 loci and characterization of the BCL11A fetal hemoglobin locus. *Blood Cells Mol Dis*. 2010;45(2):140-146.
46. O'Neill D, Yang J, Erdjument-Bromage H, Bornschlegel K, Tempst P, Bank A. Tissue-specific and developmental stage-specific DNA binding by a mammalian SWI/SNF complex associated with human fetal-to-adult globin gene switching. *Proc Natl Acad Sci U S A*. 1999;96(2):349-354.
47. Calzolari R, McMorrow T, Yannoutsos N, Langeveld A, Grosveld F. Deletion of a region that is a candidate for the difference between the deletion forms of hereditary persistence of fetal hemoglobin and deltabeta-thalassemia affects beta- but not gamma-globin gene expression. *EMBO J*. 1999;18(4):949-958.
48. Gaensler KM, Zhang Z, Lin C, Yang S, Hardt K, Flebbe-Rehwaltd L. Sequences in the (A)gamma-delta intergenic region are not required for stage-specific regulation of the human beta-globin gene locus. *Proc Natl Acad Sci U S A*. 2003;100(6):3374-3379.
49. Liu X, Zhang Y, Chen Y, et al. In Situ Capture of Chromatin Interactions by Biotinylated dCas9. *Cell*. 2017;170(5):1028-1043 e1019.
50. Huang P, Keller CA, Giardine B, et al. Comparative analysis of three-dimensional chromosomal architecture identifies a novel fetal hemoglobin regulatory element. *Genes Dev*. 2017;31(16):1704-1713.

51. Kiefer CM, Lee J, Hou C, et al. Distinct Ldb1/NLI complexes orchestrate gamma-globin repression and reactivation through ETO2 in human adult erythroid cells. *Blood*. 2011;118(23):6200-6208.
52. Joly P, Lacan P, Garcia C, Couprie N, Francina A. Identification and molecular characterization of four new large deletions in the beta-globin gene cluster. *Blood Cells Mol Dis*. 2009;43(1):53-57.
53. Galanello R. SCREENING AND DIAGNOSIS FOR HAEMOGLOBIN DISORDERS. *Prevention of Thalassaemias and Other Haemoglobin Disorders: Volume 1: Principles 2nd edition*. 2013.
54. Zertal-Zidani S, Ducrocq R, Weil-Olivier C, Elion J, Krishnamoorthy R. A novel delta beta fusion gene expresses hemoglobin A (HbA) not Hb Lepore: Senegalese delta(0)beta(+) thalassemia. *Blood*. 2001;98(4):1261-1263.
55. Bire S, Casteret S, Piegu B, et al. Mariner Transposons Contain a Silencer: Possible Role of the Polycomb Repressive Complex 2. *PLoS Genet*. 2016;12(3):e1005902.
56. Ogbourne S, Antalis TM. Transcriptional control and the role of silencers in transcriptional regulation in eukaryotes. *Biochem J*. 1998;331 (Pt 1):1-14.
57. Altrock PM, Brendel C, Renella R, Orkin SH, Williams DA, Michor F. Mathematical modeling of erythrocyte chimerism informs genetic intervention strategies for sickle cell disease. *Am J Hematol*. 2016;91(9):931-937.
58. Walters MC, Patience M, Leisenring W, et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. *Biol Blood Marrow Transplant*. 2001;7(12):665-673.
59. Gaziev J, Lucarelli G. Stem cell transplantation for hemoglobinopathies. *Curr Opin Pediatr*. 2003;15(1):24-31.
60. Rahmig S, Kronstein-Wiedemann R, Fohgrub J, et al. Improved Human Erythropoiesis and Platelet Formation in Humanized NSGW41 Mice. *Stem Cell Reports*. 2016;7(4):591-601.

61. Fiorini C, Abdulhay NJ, McFarland SK, et al. Developmentally-faithful and effective human erythropoiesis in immunodeficient and Kit mutant mice. *Am J Hematol*. 2017;92(9):E513-E519.
62. Dang Y, Jia G, Choi J, et al. Optimizing sgRNA structure to improve CRISPR-Cas9 knockout efficiency. *Genome Biol*. 2015;16:280.
63. Romero Z, Urbinati F, Geiger S, et al. beta-globin gene transfer to human bone marrow for sickle cell disease. *The Journal of clinical investigation*. 2013.
64. Ribeil JA, Hacein-Bey-Abina S, Payen E, et al. Gene Therapy in a Patient with Sickle Cell Disease. *N Engl J Med*. 2017;376(9):848-855.
65. Wienert B, Funnell AP, Norton LJ, et al. Editing the genome to introduce a beneficial naturally occurring mutation associated with increased fetal globin. *Nature communications*. 2015;6:7085.
66. Wienert B, Martyn GE, Kurita R, Nakamura Y, Quinlan KGR, Crossley M. KLF1 drives the expression of fetal hemoglobin in British HPFH. *Blood*. 2017.
67. DeWitt MA, Magis W, Bray NL, et al. Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells. *Sci Transl Med*. 2016;8(360):360ra134.
68. Hoban MD, Cost GJ, Mendel MC, et al. Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells. *Blood*. 2015;125(17):2597-2604.
69. Genovese P, Schiroli G, Escobar G, et al. Targeted genome editing in human repopulating haematopoietic stem cells. *Nature*. 2014;510(7504):235-240.
70. Chang KH, Smith SE, Sullivan T, et al. Long-term engraftment and fetal globin reactivation upon genome editing of BCL11A in bone marrow-derived CD34+ hematopoietic stem and progenitor cells. *Molecular Therapy: Methods & Clinical Development*. 2017;S2329-0501(17)30003-7.

FIGURE LEGENDS

Figure 1. Integration of mutational and epigenetic analyses of the β -globin locus.

Genomic deletions mapped in thalassemic patients and HPFH individuals are indicated with black bars (upper panel). We report the 10 HPFH mutations removing the 3.5-kb region and the 13 β -thalassemia-associated deletions, which do not include this region. The 13.6-kb, the 7.2-kb Corfu and the 3.5-kb target regions are depicted as red bars. The 3.5-kb region contains a putative BCL11A binding site and several GATA1 binding sites (retrieved from ^{27,31,45}), SNPs associated with high HbF levels, and a 250-bp polypyrimidine-rich sequence targeted by the PYR complex. We analyzed the histone modification pattern of the β -globin locus in human adult and fetal erythroblasts²⁷ (in dark and light blue, respectively; lower panel). Epigenetic modifications typical of active chromatin regions, such as H3K27 acetylation (H3K27ac), H3K4 trimethylation (H3K4me3), H3K36 trimethylation (H3K36me3), and RNA polymerase II binding (PolII), mark the β - and δ -globin and the γ -globin genes in adult and fetal erythroblasts, respectively. Typical repressive chromatin markers (H3K9 trimethylation, H3K9me3 and H3K27 trimethylation, H3K27me3) were absent in the β -globin locus of both adult and fetal erythroblasts. The 3.5-kb target region, as well as inactive γ -globin genes, were preferentially enriched in H3K36 dimethylation (H3K36me2) in adult cells. HBB: β -globin gene; HBD: δ -globin gene; HBBP1: β -globin pseudogene 1; BGLT3: β -globin locus transcript 3 gene; HBG1: A γ -globin gene; HBG2: G γ -globin gene. The enhancer located 3' to the poly(A) site of the β -globin gene is indicated as HBB enhancer.

Figure 2. Targeting of a 13.6-kb genomic region in the β -globin locus re-activates γ -globin expression in the adult HUDEP-2 erythroid cell line. HUDEP-2 cells were transfected with plasmids carrying Cas9-GFP and gRNA pairs targeting the 13.6-kb, 7.2-kb and 3.5-kb regions. Cells treated only with Cas9-GFP plasmid were used as control (ctr).

GFP⁺ cells were FACS-sorted and differentiated into mature erythroblasts. (A) Representative images of May-Grunwald-Giemsa stained undifferentiated (day 0) and differentiated (day 9) cultures. Original magnification 20X. Scale bars, 50 μ m (left panels). Bars indicate the percentage cell number for each erythroblast population after differential counting (right panel). Similar proportions of the different erythroid precursors were observed in control and genome-edited cultures. (B) qRT-PCR analysis of γ (A γ +G γ)-, δ - and β -globin mRNA levels in differentiated samples. Results were normalized to α -globin. Error bars denote standard deviation. (C) Representative FACS analyses of HbF⁺ cells (F-cells). Data are expressed as mean \pm SEM of 3 experiments. (D) RP-HPLC chromatograms showing peaks corresponding to α -globin and β -like globins in differentiated HUDEP-2 samples. The ratio of α chains to non- α chains is indicated in brackets. (E) Quantification of γ (A γ +G γ)-globin and β -globin protein levels, as assessed by RP-HPLC. β -like globin expression was normalized to α -globin. Targeting the 13.6-kb region, but not the 3.5-kb putative HbF silencer and the 7.2-kb region, reduced β -globin chain levels and strongly increased γ -globin chain expression. δ -globin protein levels were decreased only in 7.2-kb and 3.5-kb genome-edited samples.

Figure 3. HbF re-activation occurs predominantly in HUDEP-2 clones harboring bi-allelic rearrangements of the 13.6-kb target region. Control and genome-edited bulk populations were cloned by limiting dilution to isolate cells harboring bi-allelic or mono-allelic modifications of the 13.6-kb target region. We selected and differentiated 11 control (ctr), 4 bi-allelic deleted (del/del), 4 mono-allelic deleted (del/wt), 5 bi-allelic inverted (inv/inv) and 5 mono-allelic inverted (inv/wt) clones. (A) Sanger sequencing of deletion and inversion junctions in genome-edited clones. Top rows show the predicted junction sequences (in bold). The expected deletion and inversion junctions with small InDels were observed in the majority of genome-edited alleles. In two alleles, we detected larger deletions (14.1 and 14.9 kb) removing 527 and 1319 bp upstream and downstream of the 13.6-kb region,

respectively. In one allele, we detected a shorter deletion (11.6 kb), leaving 2001 bp at the 3' end of the 13.6-kb region (*). No difference in HbF expression was observed amongst these clones regardless of the deletion. The frequency of each event is calculated as: (number of alleles harboring an identical deletion or inversion junction) / (total number of deleted or inverted alleles). Arrows indicate the predicted junction sites. Dashes and dots represent deleted and hidden nucleotides, respectively. Inserted nucleotides are displayed in lowercase.

(B) qRT-PCR analysis of γ ($A\gamma+G\gamma$)-, δ - and β -globin transcripts in differentiated clones. All samples were normalized to α -globin. Error bars represent SEM. **** $P<0.0001$, *** $P<0.001$, ** $P<0.01$, * $P<0.05$ (unpaired two-tailed Student's t-test vs ctr).

(C) Representative FACS plots showing the percentage of F-cells in differentiated HUDEP-2 clones. The proportion of HbF⁺ cells was significantly higher in genome-edited vs control clones ($P<0.0001$). Data are displayed as mean \pm SEM. Clones harboring a bi-allelic inversion of the 13.6-kb regions tend to show higher γ -globin expression at both mRNA and protein levels, compared to clones harboring a bi-allelic deletion.

(D) 3C analysis of chromatin interactions between the LCR and the γ -globin promoters in differentiated clones (2 controls, 2 del/del and 2 inv/inv clones). A higher interaction frequency was observed in clones harboring a bi-allelic re-arrangement, as compared to control clones. The interaction frequencies were normalized to the cross-linking frequency in the ERCC3 locus. The hypersensitive sites of the LCR are indicated (HS1, HS2, HS3 and HS4). We used as anchor a genomic fragment containing HS3 (black rectangle). HindIII restriction sites are depicted as black triangles. Black circles indicate the β -like globin promoters. Distances on x-axis are in kb counting from the TSS of the HBE1 gene.

(E) Analysis of H3K27 acetylation at γ -globin promoters in differentiated clones (2 controls, 2 del/del and 2 inv/inv clones). γ -globin promoters were highly enriched in H3K27ac in del/del and inv/inv clones. DEFB122 genomic region served as negative control (Neg. ctr). Error bars indicate standard deviations.

Figure 4. Selection of therapeutic targets for γ -globin re-activation in erythroblasts derived from clinically relevant HSPC. HSPC derived from healthy donors were transfected with plasmids carrying Cas9-GFP and gRNAs targeting the 13.6-, 7.2- and 3.5-kb regions. (A) Flow cytometry sorting strategy of control and genome-edited cells. GFP⁺ HSPC were FACS-sorted from Cas9-only (ctr-1) and Cas9+gRNAs samples (13.6-, 7.2- and 3.5-kb). Data are expressed as mean \pm SEM of 7 independent experiments. (B) Assessment of deletion and inversion efficiency by ddPCR. FACS-sorted control and genome-edited (13.6-kb, 7.2-kb and 3.5-kb) cells were differentiated in liquid culture towards the erythroid lineage. Data represent the mean \pm standard deviation (SD) of at least 2 independent experiments. (C) qRT-PCR analysis of γ (A γ +G γ)-, δ - and β -globin transcripts in mature erythroblasts derived from GFP⁺ HSPC. mRNA levels were normalized to α -globin. γ -globin expression levels were significantly increased in 13.6-kb genome-edited cells compared to control sample. A modest increase in γ -globin mRNA were detected in 7.2-kb and 3.5-kb genome-edited samples. A robust and significant β -globin downregulation was observed in 13.6-kb genome-edited erythroblasts as compared to control cells. *P<0.05, **P<0.01; ***P<0.001 (two-way ANOVA – Bonferroni’s multiple comparisons test vs ctr-1). Data represent the mean \pm SD of at least 2 independent experiments. (D) Representative FACS histograms showing the increase in both the percentage of F-cells and the MFI (in brackets) in mature erythroblasts derived from GFP⁺ genome-edited HSPC in comparison with control sample (Cas9-only cells; ctr-1).

Figure 5. Robust HbF up-regulation in HSPC-derived erythroblasts upon genome editing of the 13.6-kb region. (A) Assessment of deletion and inversion efficiency by ddPCR in mature erythroblasts and erythroid progenitors (BFU-E) derived from GFP⁺ genome-edited healthy donor and SCD HSPC. Data represent the mean \pm SEM of 7 independent experiments. (B) Genotype of single colonies derived from GFP⁺ HSPC. The occurrence of deletion and

inversion events was assessed in randomly picked BFU-E by PCR (2 healthy donors; n=100). (C) Sanger sequencing of deletion and inversion junctions in single BFU-E (n=40). Top rows indicate the predicted junction sequences (in bold). The expected deletion and inversion junctions with small InDels were observed in the majority of genome-edited alleles. In two alleles, we detected the insertion of 354 bp (*) and 373 bp (^). The frequency of each event is calculated as: (number of alleles harboring an identical deletion or inversion junction) / (total number of deleted or inverted alleles). Arrows indicate the predicted junction sites. Dashes represent deleted nucleotides. Inserted nucleotides are displayed in lowercase. (D) qRT-PCR analysis of γ ($A\gamma+G\gamma$)-, δ - and β -globin transcripts in mature erythroblasts derived from 13.6-kb genome-edited HSPC. mRNA levels were expressed as fold change vs control cells (ctr-1). γ -globin expression levels were significantly increased in genome-edited compared to control samples (* $P<0.01$; unpaired t-test two-tailed). A significant β -globin downregulation was detected in edited cells in comparison to control (* $P<0.05$; unpaired t-test two-tailed). δ -globin expression was decreased in genome-edited samples. Data represent the mean \pm SEM of 7 independent experiments. (E) Representative FACS histograms showing the percentage of F-cells and the MFI of HbF immunostaining (in brackets) in mature erythroblasts derived from GFP⁺ genome-edited (13.6-kb) HSPC of two healthy donors. GFP⁺ cells from Cas9-only samples (ctr-1) and GFP⁻ cells from Cas9+gRNAs cultures (ctr-2) served as controls. (F) RP-HPLC chromatograms showing peaks corresponding to α -globin and β -like globins in genome edited and control samples. The expression of a common A γ T chain variant (63) was detected in samples derived from healthy donor 2. The ratio of α chains to non- α chains (in brackets) was unchanged in CRISPR/Cas9-modified samples. (G-H) Quantification of γ - ($A\gamma+G\gamma$), β - and δ - globin protein levels. β -like globin expression was normalized to α -globin (G). Relative abundance of β -like chains was calculated as percentage of total β -like ($\beta + \gamma + \delta$) globins (H). Targeting the 13.6-kb region increased γ -globin chain expression and decreased β -globin protein levels. δ -globin protein levels were unaffected, suggesting an increased

translation of the residual δ -globin transcripts in the absence of β -globin mRNA. Alternatively, the reduced β -chain synthesis favors the incorporation of the δ -globin chain in the Hb tetramers.

Figure 6. CRISPR/Cas9-mediated induction of fetal hemoglobin expression improves the RBC sickling phenotype. Bone marrow (donor 1) and mobilized (donor 2) SCD CD34⁺ cells were transfected with plasmids carrying Cas9-GFP and gRNAs targeting the 13.6-kb region. Upon FACS-sorting, GFP⁺ genome-edited (13.6-kb) HSPC were terminally differentiated in RBC using a 3-phase liquid erythroid culture system (58). GFP⁺ cells from Cas9-only samples (ctr-1) and GFP⁻ cells from Cas9+gRNAs cultures (ctr-2) were used as controls. (A) FACS analysis of HbF expression in control and genome-edited RBC. The fraction of F-cells and the MFI of HbF immunostaining (in brackets) are displayed in the histograms. (B) RP-HPLC profiles of control and genome-edited RBC (donor 1). The ratio of α chains to non- α chains is indicated in brackets. (C-D) Quantification of γ (A γ +G γ)-globins and sickle β -globin protein levels by RP-HPLC. Globin chain expression was normalized to α -globin (C). Relative abundance of β -like chains was calculated as fraction of total β -like ($\beta + \gamma$) globins (D). (E) In vitro sickling assay measuring the proportion of sickled RBC under hypoxic conditions (0% O₂) (left panel). The percentage of sickled cells was calculated as: (sickled RBC count)/(total RBC count). At least 300 enucleated cells and 10 fields per time-point were analyzed for each sample. Data are expressed as mean \pm SEM. **** P<0.0001 (two-way ANOVA – Tukey’s multiple comparisons test vs ctr-1 and ctr-2). Representative microscopy images of RBC before (0 minutes) and after (60 minutes) de-oxygenation are shown in the right panel. Black and white arrowheads indicate sickled cells and non-sickled cells, respectively, under hypoxic conditions. Original magnification 40X. Scale bars, 50 μ m.

Figure 1




Figure 2

Journal.org by guest on March 10, 2018. For personal use only.






Figure 3


A




B



C



D



E






Figure 4


A



B



C



D




Figure 5






Figure 6

From www.bloodjournal.org by guest on March 10, 2018. For personal use only.


A




B





C



D



E





blood[®]

Prepublished online March 8, 2018;
doi:10.1182/blood-2017-10-811505

Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β -globin locus

Chiara Antoniani, Vasco Meneghini, Annalisa Lattanzi, Tristan Felix, Oriana Romano, Elisa Magrin, Leslie Weber, Giulia Pavani, Sara El Hoss, Ryo Kurita, Yukio Nakamura, Thomas J. Cradick, Ante S. Lundberg, Matthew Porteus, Mario Amendola, Wassim El Nemer, Marina Cavazzana, Fulvio Mavilio and Annarita Miccio

Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:
<http://www.bloodjournal.org/site/misc/rights.xhtml#reprints>

Information about subscriptions and ASH membership may be found online at:
<http://www.bloodjournal.org/site/subscriptions/index.xhtml>

Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include digital object identifier (DOIs) and date of initial publication.